Alston & Bird client TG Therapeutics, a biopharmaceutical company developing novel treatments for certain blood cancers and autoimmune diseases, closed an upsized public offering of common stock that raised $300 million.
The offering was the fourth capital raise by TG Therapeutics that Alston & Bird has advised on this year and was greater than anticipated at the launch. The offering also included a 30-day option to purchase up to an additional 948,000 shares of common stock that the company granted the underwriters, which they exercised before closing.
TG Therapeutics will use the proceeds from the offering, which closed December 17, to fund the further development and commercialization of two therapies for hematological malignancies and autoimmune diseases, as well as for other pharmaceutical products.
Headquartered in New York City, TG Therapeutics is listed on the Nasdaq with a market cap of almost $5 billion.
Advising TG Therapeutics in its most recent stock offering is an Alston & Bird team led by partner Mark McElreath and associates Zack Young and Laura Giambalvo (Corporate & Business Transactions); associate Helena Wong (Financial Services & Products); and partner Natalie Clayton and associate Maddy Byrd (Intellectual Property).